Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 25
- Rekrutierung läuftAdvancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotypingMolekulare Marker
- Rekrutierung läuftA Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects with Advanced Solid TumorsAMG 994, AMG 404
- Rekrutierung läuftA Randomized, Open - Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion - positive, Metastatic Non - Small Cell Lung Cancer.BLU - 667Molekulare Marker
- Rekrutierung läuftA phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftAn open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinibMolekulare Marker
- Rekrutierung läuftMulticenter Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-squamous NSCLC or Extensive-stage SCLC Under First-line Treatment With Atezolizumab and Platinum-based ChemotherapyMolekulare Marker
- Rekrutierung läuftA phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced squamous NSCLC (sqNSCLC) harboring FGFR genetic alterations after relapse of standard therapyMolekulare Marker
- Rekrutierung läuftA Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSCA MarkerMolekulare Marker
- Rekrutierung läuftNIS zur Beobachtung von Wirkungseffekten von Atezolizumab in der alltäglichen Routine bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht kleinzelligem Lungencarcinom nach vorheriger ChemotherapieMolekulare Marker